172 related articles for article (PubMed ID: 36268758)
1. Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: Three-year follow-up of a multicentre, single arm, IDEAL phase 2b trial.
Gallo G; Picciariello A; Pietroletti R; Novelli E; Sturiale A; Tutino R; Laforgia R; Moggia E; Pozzo M; Roveroni M; Bianco V; Realis Luc A; Giuliani A; Diaco E; Naldini G; Trompetto M; Perinotti R; D'Andrea V; Lobascio P
Colorectal Dis; 2023 Mar; 25(3):386-395. PubMed ID: 36268758
[TBL] [Abstract][Full Text] [Related]
2. A multicentre, open-label, single-arm phase II trial of the efficacy and safety of sclerotherapy using 3% polidocanol foam to treat second-degree haemorrhoids (SCLEROFOAM).
Gallo G; Pietroletti R; Novelli E; Sturiale A; Tutino R; Lobascio P; Laforgia R; Moggia E; Pozzo M; Roveroni M; Bianco V; Luc AR; Giuliani A; Diaco E; Naldini G; Trompetto M; Perinotti R; Sammarco G
Tech Coloproctol; 2022 Aug; 26(8):627-636. PubMed ID: 35334004
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial.
Moser KH; Mosch C; Walgenbach M; Bussen DG; Kirsch J; Joos AK; Gliem P; Sauerland S
Int J Colorectal Dis; 2013 Oct; 28(10):1439-47. PubMed ID: 23775099
[TBL] [Abstract][Full Text] [Related]
4. Polidocanol foam sclerotherapy in the treatment of hemorrhoidal disease in patients with bleeding disorders: a multicenter, prospective, cohort study.
Salgueiro P; Rei A; Garrido M; Rosa B; Oliveira AM; Pereira-Guedes T; Morais S; Castro-Poças F
Tech Coloproctol; 2022 Aug; 26(8):615-625. PubMed ID: 35217937
[TBL] [Abstract][Full Text] [Related]
5. Combined rubber band ligation with 3% polidocanol foam sclerotherapy (ScleroBanding) for the treatment of second-degree haemorrhoidal disease: a video vignette.
Bracchitta S; Bracchitta LM; Pata F
Colorectal Dis; 2021 Jun; 23(6):1585-1586. PubMed ID: 33660907
[No Abstract] [Full Text] [Related]
6. Preliminary Results of the First 50 Patients Undergoing Sclerotherapy for II-Degree Hemorrhoidal Disease Using an Automated Device.
Goglia M; Nigro C; Aurello P; Diaco E; Trompetto M; Gallo G
Front Surg; 2022; 9():882030. PubMed ID: 35495738
[TBL] [Abstract][Full Text] [Related]
7. Use of video-guided sclerotherapy with 3% polidocanol foam for symptomatic second-degree haemorrhoidal disease - a video vignette.
Skowronski A; Diaco E; Trompetto M; Gallo G
Colorectal Dis; 2020 Sep; 22(9):1198-1199. PubMed ID: 32180308
[No Abstract] [Full Text] [Related]
8. The use of sclerotherapy with polidocanol foam in the treatment of second-degree haemorrhoidal disease - a video vignette.
Lobascio P; Minafra M; Laforgia R; Giove C; Trompetto M; Gallo G
Colorectal Dis; 2019 Feb; 21(2):244-245. PubMed ID: 30485654
[No Abstract] [Full Text] [Related]
9. Short-Term Results of Sclerotherapy with 3% Polidocanol Foam for Symptomatic Second- and Third-Degree Hemorrhoidal Disease.
Lobascio P; Laforgia R; Novelli E; Perrone F; Di Salvo M; Pezzolla A; Trompetto M; Gallo G
J Invest Surg; 2021 Oct; 34(10):1059-1065. PubMed ID: 32290709
[TBL] [Abstract][Full Text] [Related]
10. Sclerotherapy using 2 % polidocanol foam in the treatment of hemorrhoidal disease - a single-center experience.
Figueiredo LM; Bordalo Ferreira F; Rafael MA; Oliveira AM
Rev Esp Enferm Dig; 2022 Mar; 114(3):185-186. PubMed ID: 34517712
[TBL] [Abstract][Full Text] [Related]
11. Treatment of male varicoceles by transcatheter polidocanol foam sclerotherapy: evaluation of clinical success, complications, and patients' satisfaction with regard to alternative techniques.
Ali A; Wirth S; Treitl KM; Treitl M
Eur Radiol; 2015 Oct; 25(10):2889-97. PubMed ID: 25796582
[TBL] [Abstract][Full Text] [Related]
12. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
Uncu H
Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
Rabe E; Otto J; Schliephake D; Pannier F
Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
[TBL] [Abstract][Full Text] [Related]
14. Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report.
Itou C; Koizumi J; Hashimoto T; Myojin K; Kagawa T; Mine T; Imai Y
Cardiovasc Intervent Radiol; 2014 Jun; 37(3):800-4. PubMed ID: 24170168
[TBL] [Abstract][Full Text] [Related]
15. Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient technique for venous malformations.
Yang X; Chen H; Gu H; Jin Y; Hu L; Hua C; Wang Y; Sun Y; Yu W; Lin X
J Vasc Surg Venous Lymphat Disord; 2020 Nov; 8(6):1066-1073. PubMed ID: 32284311
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sclerotherapy with polidocanol in children with internal hemorrhoids.
Watanabe T; Ohno M; Tahara K; Tomonaga K; Ogawa K; Takezoe T; Fuchimoto Y; Fujino A; Kanamori Y
Pediatr Int; 2021 Jul; 63(7):813-817. PubMed ID: 33045763
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up.
Blaise S; Bosson JL; Diamand JM
Eur J Vasc Endovasc Surg; 2010 Jun; 39(6):779-86. PubMed ID: 20206556
[TBL] [Abstract][Full Text] [Related]
18. Foam sclerotherapy using polidocanol for balloon-occluded retrograde transvenous obliteration (BRTO).
Choi SY; Won JY; Kim KA; Lee DY; Lee KH
Eur Radiol; 2011 Jan; 21(1):122-9. PubMed ID: 20737152
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial.
Ukritmanoroat T
J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S35-40. PubMed ID: 21717876
[TBL] [Abstract][Full Text] [Related]
20. Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease.
Gallo G; Ronconi M; Trompetto M
Updates Surg; 2021 Oct; 73(5):2029-2030. PubMed ID: 33660166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
